Amifostine
- Generic Name
- Amifostine
- Brand Names
- Ethyol
- Drug Type
- Small Molecule
- Chemical Formula
- C5H15N2O3PS
- CAS Number
- 20537-88-6
- Unique Ingredient Identifier
- ILA426L95O
- Background
A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
- Indication
For reduction in the cumulative renal toxicity in patients with ovarian cancer (using cisplatin) and moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.
- Associated Conditions
- Dry Mouth, Nephrotoxicity, Prophylaxis of Radiation proctitis
Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities
- Conditions
- Head and Neck CancerLung Cancer
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2005-09-27
- Lead Sponsor
- The Dale & Frances Hughes Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT00130143
- Locations
- 🇺🇸
The Dale & Frances Hughes Cancer Center, East Stroudsburg, Pennsylvania, United States
Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes
- Conditions
- Myelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 10
- Registration Number
- NCT00098683
- Locations
- 🇺🇸
Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸St. Vincent Indianapolis Hospital, Indianapolis, Indiana, United States
Randomized Amifostine For SCCHN
- Conditions
- Head and Neck CancerMucositisChemotherapeutic Agent ToxicityRadiation ToxicityXerostomia
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 58
- Registration Number
- NCT00095927
- Locations
- 🇺🇸
Goodall Hospital, Sanford, Maine, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
- Conditions
- Chronic Myeloproliferative DisordersDrug/Agent Toxicity by Tissue/OrganLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesPrecancerous ConditionUnspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT00004036
- Locations
- 🇺🇸
Cleveland Clinic Cancer Center, Cleveland, Ohio, United States
Amifostine in Treating Patients With Cancer Who Have Neurological Changes Caused by Chemotherapy
- Conditions
- Drug/Agent Toxicity by Tissue/OrganUnspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-09-10
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Rush North Shore Medical Center
- Registration Number
- NCT00003252
- Locations
- 🇺🇸
Rush North Shore Medical Center, Skokie, Illinois, United States
Amifostine in Treating Patients With Myelodysplastic Syndrome
- First Posted Date
- 2004-09-06
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT00003048
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer
- Conditions
- Ovarian CancerLung CancerNeurotoxicity
- First Posted Date
- 2004-09-06
- Last Posted Date
- 2012-09-21
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 80
- Registration Number
- NCT00003072
- Locations
- 🇺🇸
Oncology Service of San Francisco General Hospital Medical Center, San Francisco, California, United States
🇺🇸UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
🇺🇸UCSF/Mt. Zion Cancer Center, San Francisco, California, United States
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer
- Conditions
- Ovarian CancerPrimary Peritoneal Cavity Cancer
- Interventions
- Biological: filgrastimProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2004-08-24
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 11
- Registration Number
- NCT00003136
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-08-16
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- State University of New York - Upstate Medical University
- Target Recruit Count
- 20
- Registration Number
- NCT00003555
- Locations
- 🇺🇸
State University of New York - Upstate Medical University, Syracuse, New York, United States
Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer
- Conditions
- Drug/Agent Toxicity by Tissue/OrganHead and Neck CancerRadiation Toxicity
- First Posted Date
- 2004-08-13
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 46
- Registration Number
- NCT00003251
- Locations
- 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.